VIM and breast cancer: Several important molecular targets were identified, such as vimentin (VIM), NFκB, β-tubulin, uPA (PLAU), interleukin-6 (IL-6), STAT3 or ESR, and more recently in vivo mouse models have confirmed WA efficacy in mammary tumors and BC xenografts [26–34].